4.7 Article

Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer's disease

Journal

SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep32583

Keywords

-

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir, Inc.
  13. Eisai Inc.
  14. Elan Pharmaceuticals, Inc.
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd
  18. Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  23. Johnson & Johnson Pharmaceutical Research & Development LLC.
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC.
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research
  37. Northern California Institute for Research and Education
  38. NIA [P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, P50 AGO16574, R01 AGO32990, U01 AGO461139, R01 AGO18023]
  39. NINDS [R01 NS080820]
  40. CurePSP Foundation
  41. Mayo Foundation
  42. National Institute of Neurological Disorders and Stroke [U24 NS072026]
  43. National Institute on Aging [P30 AG19610]
  44. Arizona Department of Health Services [211002]
  45. Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]
  46. Michael J. Fox Foundation for Parkinsons Research
  47. NIDS [R01 NS080820]

Ask authors/readers for more resources

Among the genetic factors known to increase the risk of late onset Alzheimer's diseases (AD), the presence of the apolipoproteine e4 (APOE4) allele has been recognized as the one with the strongest effect. However, despite decades of research, the pathogenic role of APOE4 in Alzheimer's disease has not been clearly elucidated yet. In order to investigate the pathogenic action of APOE4, we applied a systems biology approach to the analysis of transcriptomic and genomic data of APOE44 vs. APOE33 allele carriers affected by Alzheimer's disease. Network analysis combined with a novel technique for biomarker computation allowed the identification of an alteration in aging-associated processes such as inflammation, oxidative stress and metabolic pathways, indicating that APOE4 possibly accelerates pathological processes physiologically induced by aging. Subsequent integration with genomic data indicates that the Notch pathway could be the nodal molecular mechanism altered in APOE44 allele carriers with Alzheimer's disease. Interestingly, PSEN1 and APP, genes whose mutation are known to be linked to early onset Alzheimer's disease, are closely linked to this pathway. In conclusion, APOE4 role on inflammation and oxidation through the Notch signaling pathway could be crucial in elucidating the risk factors of Alzheimer's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available